Chris Leamon

Chris Leamon

Company: Fusion Pharmaceuticals

Job title: Chief Scientific Officer


Targeted Alpha Particle Therapy: Spanning Small Molecules, Peptides and Antibodies 11:30 am

Is targeted radiotherapy any better than targeted chemotherapy? The pursuit of 225Ac. A potent payload for targeted therapy Ligand diversity. Who knows what’s optimal for solid tumor therapy?Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.